The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...

Packaged foods may soon have warning labels about how much sodium, saturated fats, and added sugars they contain in an effort ...

CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

Asians, non-Hispanic Blacks and Hispanics were significantly less likely than whites to use obesity-management medications to lower their weight compared with whites, new research suggests. The ...

BMI has long been falling out of favor. When the American Medical Association urged downgrading BMI in 2023, it blamed its ...

New FDA draft guidance for drugmakers focuses on trial design for developing obesity treatments. Read more here.

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Biden leaving 11th-hour health measures ...

Sen. Bernie Sanders (I-VT) proposed in February 2024 that the FDA place warning labels about the risk of developing Type 2 diabetes or obesity on foods with high saturated fat, added sugar ...

Eli Lilly (NYSE:LLY) CEO Dave Ricks said Monday that the company's GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early 2026. In an interview with Bloomberg TV ...